Skip to content

MIDCAB Versus DES in Proximal LAD Lesions

Randomised Comparison of Minimally Invasive Direct Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention With Drug-eluting Stents in Patients With Proximal Stenosis of the Left Anterior Descending Coronary Artery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00299429
Enrollment
130
Registered
2006-03-06
Start date
2003-01-31
Completion date
2008-07-31
Last updated
2018-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Stent, drug-eluting stent, Minimally invasive bypass surgery, left anterior descending

Brief summary

Percutaneous coronary intervention with a sirolimus-coated stent compared to minimally invasive bypass surgery in patients with isolated proximal left anterior descending coronary arteries in terms of non-inferiority of an end point combining mortality, acute myocardial infarction and rate of reintervention of the target vessel within one year.

Interventions

PROCEDUREStenting and minimally invasive bypass surgery
PROCEDUREPCI with DES

PCI with DES

Sponsors

Cordis Medizinische Apparate GmbH
CollaboratorOTHER
University of Leipzig
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Single-vessel disease of the proximal LAD with a stenosis \> 50% (multivessel disease only if further coronary vessel stenoses do not require treatment) 2. Patients with angina pectoris (CCS 1-4) 3. Asymptomatic patients if clear signs of ischemia in the segments supplied by the LAD as assessed by bicycle ergometry or treadmill and/or scintigraphically and/or stress echo 4. Patients for whom both methods of treatment are equally possible 5. Consensus between the cardiac surgeon and the cardiologist that both inclusion and

Exclusion criteria

are met in the selected case 6. Informed consent of the patient.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiac events12 months

Secondary

MeasureTime frame
Perioperative complications30 days
CCS-Classification12 months
cost-effectiveness12 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026